Suggested Formulations for Mometasone Furoate

被引：1
作者：
Melhorn, Stefanie [1 ]
Staubach, Petra [2 ]
机构：
[1] Avoxa Mediengrp Deutsch Apotheker GmbH, Deutsch Arzneimittel Codex Neues Rezeptur Formula, Carl Mannich Str 26, D-65760 Eschborn, Germany
[2] Univ Med Mainz, Hautklin & Poliklin, Mainz, Germany
来源：
HAUTARZT | 2019年 / 70卷 / 05期
关键词：
D O I：
10.1007/s00105-019-4406-8
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：392 / 394
页数：3
相关论文
共 50 条
  • [31] Assessment of the pharmacological properties of the metabolites of mometasone furoate
    Sahasranaman, S
    Issar, M
    Hochhaus, G
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10) : 1196 - 1196
  • [32] Mometasone Furoate and Nasal Vascularisation in Allergic Patients
    Kujundzic, Milodar
    Babarovic, Emina
    Petkovic, Marija
    Pavlovic-Ruzic, Ira
    Coklo, Miran
    Zamolo, Gordana
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 (01) : 127 - 130
  • [33] A review of mometasone furoate/formoterol in the treatment of asthma
    Westergaard, Christian Grabow
    Porsbjerg, Celeste
    Backer, Vibeke
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (03) : 339 - 346
  • [34] Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris
    Tiplica, G-S
    Salavastru, C. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (08) : 905 - 912
  • [35] Mometasone furoate in the treatment of seasonal allergic rhinitis
    Stuck, BA
    Hummel, T
    Hecksteden, K
    Czajkowski, J
    Klimek, L
    Hüttenbrink, KB
    Hörmann, K
    ALLERGOLOGIE, 2003, 26 (05) : 196 - 201
  • [36] Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma (vol 70, 102068, 2021)
    Buhl, Roland
    Nikolaev, Ivan
    Tillmann, Hanns-Christian
    Vaidya, Soniya
    Bartels, Christian
    Jain, Monish
    Jauernig, Juergen
    Kerstjens, Huib A. M.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 73
  • [37] Lack of systemic activity with intranasal mometasone furoate.
    Brannan, MD
    Seiberling, M
    Cutler, DL
    Cuss, FM
    Affrime, MB
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (01) : 62 - 62
  • [38] THE RELEVANCE OF THE MOMETASONE FUROATE NASAL SPRAY IN CLINICAL PRACTICE
    Ciprandi, G.
    Varricchio, A.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (04) : 1051 - 1054
  • [39] Study of Intrinsic Stability of Mometasone Furoate in Presence of Salicylic Acid by HPTLC and Characterization, Cytotoxicity Testing of Major Degradation Product of Mometasone Furoate
    Vichare, Vijaya
    Choudhari, Vishnu P.
    Reddy, M. Venkata
    CURRENT PHARMACEUTICAL ANALYSIS, 2019, 15 (06) : 592 - 603
  • [40] Hyposmia in persistent allergic rhinitis: Effects of topical therapy with mometasone furoate and fluticasone furoate
    Catana, I
    Chirila, M.
    Bologa, R.
    Crisan, I
    Negoias, S.
    Cosgarea, M.
    ALLERGY, 2010, 65 : 719 - 720
12345